Latest news with #CatalioCapitalManagement
Business Wire
12-08-2025
- Business
- Business Wire
Amalgam Rx Secures $20M Credit Investment from Catalio Capital Management to Accelerate Medical-Grade AI™ Deployment
WILMINGTON, Del.--(BUSINESS WIRE)-- Amalgam Rx, Inc., a leader in enabling data-driven healthcare decision making, today announced a $20 million credit investment from Catalio Capital Management, a leading investment firm dedicated to backing innovative healthcare companies. The funding will accelerate the scaling of Amalgam's Medical-Grade AI solutions to further empower patients in their daily lives and providers in their clinical workflows. The funding will accelerate the scaling of Amalgam's Medical-Grade AI solutions. The senior secured term loan provides Amalgam with an initial draw of $12 million at close to continue its market expansion and refinance existing corporate debt. Amalgam will also gain access to Catalio's extensive network of life sciences leaders, including its board of advisors and 45+ Catalio Venture Partners – comprised of world-renowned, serial scientist-entrepreneurs with a proven track record in starting category-defining businesses – who will provide strategic insights to support product development and commercial growth. 'Our investment in Amalgam reflects Catalio's commitment to backing the next generation of pioneering healthcare companies. Amalgam's proven track record, scalable platform, and vision for intelligent, personalized care position them as a leader in facilitating high quality care. We're proud to support the company's next phase of growth as they continue to drive innovation at the intersection of digital health and life sciences,' said Catalio's Dr. Nicholas von Guionneau, who joins Amalgam's Board of Directors as an Observer. 'We're excited to welcome Catalio as a strategic partner through its $20 million credit investment. Catalio's deep expertise in healthcare and life sciences, combined with their expansive venture network, makes them an ideal partner as we scale. This funding will accelerate the development and deployment of our medical-grade AI platform – enhancing decision-making for both patients and providers – and advance our mission to transform chronic disease management through intelligent, personalized care,' said Ryan Sysko, Chief Executive Officer of Amalgam Rx. As healthcare increasingly adopts AI, ensuring safety, compliance, and integrity is paramount. Amalgam has spent five years developing its proprietary Medical-Grade AI, a platform engineered with built-in safeguards to meet rigorous clinical, ethical, and regulatory standards. This enables healthcare organizations to safely, quickly, and confidently harness the power of AI. Amalgam's financial advisor was KOI Capital Group and was represented by Nemphos Braue LLC. Catalio was represented by Covington & Burling LLP. About Catalio Capital Management Catalio Capital Management, LP, is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public and credit markets. Catalio has exclusive partnerships with world-renowned serial scientist-entrepreneurs from around the globe who each have extensive academic and scientific achievements and who have also started multiple well-established companies based on their research. Catalio has offices in New York, London, and Washington, D.C. Learn more about Catalio Capital Management by visiting About Amalgam Rx Amalgam Rx empowers patients and providers to make the best decisions possible—within clinical workflows and in everyday life. With a modular SaMD platform, EHR solutions, and Medical-Grade Al, Amalgam partners with global life sciences companies, health plans, and providers to reimagine care delivery. Today, Amalgam's Al-powered solutions support nearly 10 million patients across four continents and have enabled more than 70 million clinical decisions.
Yahoo
01-07-2025
- Business
- Yahoo
Catalio Capital closes over $400M Fund IV
Venture capital firm Catalio Capital Management announced today the closing of its more than $400 million Fund IV, as first reported by Bloomberg. The fund will continue the firm's thesis of backing healthcare and biotechnology companies. The firm was founded in 2020 and has made more than 100 investments, according to Pitchbook. Catalio's Fund IV, in particular, has backed 16 companies already, including the diagnostics company PinkDX and the drug discovery company Superluminal Medicines. The firm previously raised a $381 million Fund III in 2020 and a $100 million Fund II in 2019, per PitchBook. The biotech market, in particular, has not been immune to the venture downturn of the past year, followed by higher interest rates and a cooler IPO market. The market overall raised just $12 billion last year, a sharp decline from its peak of $152.3 billion in 2023, as reported by Bloomberg. Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
GlycoEra secures $130m to progress IgG4-targeted protein degrader
Biotechnology company GlycoEra has closed an oversubscribed Series B financing round, raising $130m, to support the progression of its lead immunoglobulin G4 (IgG4)-targeted protein degrader through clinical proof-of-concept. The investment will help in developing the company's pipeline of precision extracellular degraders for immunology and other indications. Spearheaded by Novo Holdings, the financing round also saw contributions from new investors, including Catalio Capital Management, QIA and LifeArc Ventures. Current investors Sofinnova Partners, Roche Ventures, Bristol Myers Squibb, and 5AM Ventures also participated in the round. Joining the syndicate were Sixty Degree Capital, Agent Capital, and MP Healthcare Venture Management, Mitsubishi Tanabe Pharma's subsidiary. GlycoEra noted that its platform is capable of targeting a wide range of extracellular proteins, and the company's bispecific degraders utilise a natural process to degrade proteins, offering a sustained removal of disease-causing proteins rapidly while eliminating systemic off-target effects. This method is said to contrast with traditional approaches, as the production of the company's degraders takes place via a single-step recombinant process, providing scalability and modularity. The company's lead programme, GE8820, aims to degrade pathogenic IgG4 autoantibodies selectively, without causing immunosuppression. GlycoEra CEO and president Ganesh Kaundinya said: 'Our lead programme, which has demonstrated deep and rapid IgG4 degradation preclinically, presents an opportunity to deliver transformative therapies to patients suffering from multiple autoimmune diseases. With this financing, we plan to initiate first-in-human clinical trials for our lead programme later this year. 'This financing is a strong validation of our science and platform, allowing us to accelerate our lead program into clinical development while advancing our robust pipeline of precision immunology medicines.' Furthermore, the company has added three new members to its board of directors: Max Klement, Matthew Hobson, Catalio Capital Management principal, and LifeArc Ventures partner Sohaib Mir, Partner. GlycoEra is based in Switzerland and operates additional offices and labs in the US. "GlycoEra secures $130m to progress IgG4-targeted protein degrader " was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
